Angioplasty Balloons Market by Product Type (Coronary Angioplasty Balloons, Peripheral Angioplasty Balloons, Neurovascular Balloons), Indication (Coronary, Peripheral), Sales Channel, End User - Global Forecast 2025-2032
Description
The Angioplasty Balloons Market was valued at USD 4.14 billion in 2024 and is projected to grow to USD 4.48 billion in 2025, with a CAGR of 8.85%, reaching USD 8.16 billion by 2032.
A concise orienting overview of clinical imperatives, care setting evolution, and device dynamics that shape procurement and innovation in angioplasty balloon technologies
This executive summary frames the contemporary angioplasty balloon landscape by situating device evolution within clinical needs, care pathway shifts, and enterprise-level priorities. Clinicians increasingly demand tools that balance acute procedural effectiveness with durable vessel patency and minimized repeat interventions, driving attention to both drug-coated balloon technologies and refinements in plain balloon mechanics. Concurrently, provider settings from high-acuity hospitals to ambulatory surgical centers reshape procedural volume distribution, influencing procurement cycles and capital allocation. The intersection of clinical efficacy, device safety profiles, and reimbursement realities determines adoption velocity across indications such as coronary and peripheral interventions, with the peripheral space further stratified by anatomical focus areas including carotid, iliac, lower limb, and renal.
In this context, industry stakeholders face a multifaceted decision environment. Device developers must align R&D priorities with evidence generation that resonates with interventional cardiologists and vascular surgeons while meeting regulatory expectations. Payers and providers increasingly evaluate devices through a value lens, prioritizing tools that demonstrably reduce downstream resource use. Therefore, the narrative underpinning angioplasty balloon development and commercialization centers on robust clinical outcomes, operational adaptability across ambulatory surgical centers and specialty clinics, and the capacity to navigate complex regulatory and procurement ecosystems without compromising patient outcomes.
An analysis of converging clinical, regulatory, and commercial forces reshaping angioplasty balloon adoption patterns and innovation priorities across care settings
The angioplasty balloon landscape has undergone substantive transformative shifts driven by converging clinical, regulatory, and commercial forces. Over recent years, the transition toward devices that address restenosis without permanent implant burdens has elevated drug-coated balloons from niche adjuncts to mainstream therapeutic considerations in peripheral interventions while prompting careful evaluation in coronary contexts. At the same time, improvements in balloon material science and delivery mechanisms have reduced procedural complications and enhanced lesion preparation, enabling safer treatment of complex anatomies such as calcified and tortuous vessels.
Moreover, stakeholder expectations now prioritize real-world evidence and patient-centric outcomes, prompting manufacturers to design trials and registries that capture durability, limb salvage, and quality-of-life metrics beyond short-term angiographic success. In parallel, health systems and payers emphasize cost-effective care pathways, thus incentivizing devices that reduce repeat procedures and hospital lengths of stay. As a result, companies face heightened pressure to demonstrate not only technical superiority or equivalence but also measurable improvements in downstream clinical and economic endpoints. These cumulative shifts compel coordinated strategies spanning clinical development, commercial positioning, and postmarket surveillance to secure durable adoption.
A detailed assessment of how 2025 cumulative tariff measures in the United States realigned supply chains, procurement practices, and manufacturing localization choices for cardiovascular device stakeholders
The introduction of cumulative United States tariff actions in 2025 created a material inflection point for supply chain decision-making and cost management in the cardiovascular device sector. Tariff-related cost pressures have prompted manufacturers and distributors to re-evaluate sourcing footprints, with many exploring greater regionalization of supply, renegotiation of supplier contracts, and stock optimization to mitigate landed cost volatility. In response, several device makers accelerated investments in domestic manufacturing capabilities or established dual-sourcing strategies to preserve continuity for high-demand product families while reducing exposure to tariff-driven margins compression.
Beyond direct cost implications, tariffs influenced strategic vendor consolidation and selection criteria, as providers and group purchasing organizations increasingly prioritized suppliers that could guarantee stable pricing and timely delivery. This shift also amplified the attractiveness of integrated supply models that bundle devices with procedural disposables and service agreements, enabling buyers to lock in predictable total cost of care. Importantly, the tariff environment reinforced the need for transparent cost components and scenario planning; procurement teams now require clearer decompositions of input cost drivers, logistics lead times, and contingency plans. Consequently, commercial negotiations and contracting structures have evolved to incorporate clauses addressing tariff pass-through, currency fluctuations, and collaborative supply risk management.
Granular segmentation intelligence revealing how product type, clinical indications across vascular territories, and diverse end-user settings intersect to shape adoption and procurement choices
Segment-specific dynamics reveal differentiated adoption pathways and commercial priorities across product, indication, and end-user classifications. Based on Product, the comparison between Drug Coated Balloon and Plain Balloon underscores diverging evidence requirements: drug-coated technologies rely on sustained clinical data to justify premium positioning given their therapeutic aim to mitigate restenosis, whereas plain balloons emphasize mechanical reliability, deliverability, and cost-efficiency for lesion preparation and short-duration interventions. Transitioning between these product categories requires careful economic and clinical rationale that resonates with both interventionalists and hospital procurement teams.
Based on Indication, contrasts between Coronary and Peripheral usage patterns shape device design and regulatory engagement strategies. Coronary applications often demand devices engineered for small-vessel precision and acute myocardial safety, while Peripheral interventions need long balloon lengths and robust profile management for tortuous anatomy; within the peripheral subset, clinical performance expectations vary across carotid, iliac, lower limb, and renal territories, each carrying unique anatomical and hemodynamic considerations that influence device selection. Based on End User, the procurement and utilization environment across Ambulatory Surgical Centers, Cardiac Centers, Hospitals, and Specialty Clinics affects product mix and service models: ambulatory centers prioritize compact logistics and rapid turnover, cardiac centers emphasize complex case capability and specialist training, hospitals balance capital investment with broad case mix, and specialty clinics focus on niche procedural excellence. These segmentation lenses intersect to create granular commercialization pathways, where clinical evidence, service support, and supply reliability determine the most viable adoption strategies for each segment.
A comprehensive view of regional regulatory diversity, clinical adoption drivers, and commercialization imperatives across the Americas, EMEA, and Asia-Pacific healthcare landscapes
Regional dynamics play a pivotal role in shaping regulatory strategies, commercial deployment, and clinical trial design across the Americas, Europe, Middle East & Africa, and Asia-Pacific. The Americas exhibit a concentration of advanced interventional programs and sophisticated payer mix considerations that accelerate evidence-driven adoption while exposing manufacturers to complex reimbursement pathways and procurement scrutiny. In contrast, regulatory pathways and healthcare reimbursement models across Europe, Middle East & Africa display heterogeneity, requiring nuanced market entry strategies that balance localized clinical partnerships and region-specific postmarket surveillance commitments.
Asia-Pacific presents both rapid procedural volume growth and diverse regulatory regimes, spurring manufacturers to tailor commercialization and manufacturing strategies for scale and affordability. Across these regions, companies must reconcile differing clinician preferences, institutional capabilities, and payer priorities; consequently, a single global commercialization model rarely suffices. Instead, regionalized product portfolios, localized clinical evidence generation, and adaptive pricing strategies become essential to navigate the variegated landscape, ensure compliance, and support sustainable adoption while enabling clinicians to access devices suited to their procedural and patient needs.
Strategic company-level perspectives highlighting how technology differentiation, clinical partnerships, and supply chain resilience drive competitive positioning and commercial success
Competitive dynamics among device manufacturers are increasingly characterized by dual vectors: technology differentiation and ecosystem services. Leading firms invest in coating chemistry improvements, balloon profile optimization, and delivery catheter ergonomics to secure clinical preference, while nimble innovators focus on niche advantages-such as specialized coatings or lesion preparation adjuncts-that target specific anatomical challenges. Strategic behaviors include alliance formation with clinical centers to generate real-world evidence, incremental product iterations to address clinician feedback, and selective acquisitions that fill technological gaps or expand geographic distribution.
Commercially, companies that combine strong clinical datasets with robust service offerings-training programs, procedural support, and outcome tracking-gain preferential access to tender processes and institutional formularies. Financially disciplined players emphasize supply chain resilience and lean manufacturing to protect margins in a pricing-constrained environment. Additionally, intellectual property around drug delivery mechanisms and coating stability remains a critical barrier to entry, prompting both defensive patent strategies and collaborative licensing arrangements. Overall, market leaders and challengers alike must balance R&D intensity with pragmatic commercialization frameworks that align evidence generation, regulatory submission timelines, and customer engagement models.
Actionable strategic imperatives for device makers and health system stakeholders to strengthen clinical evidence, stabilize supply chains, and optimize go-to-market models across care settings
Industry leaders should adopt a multifaceted approach to capitalize on clinical momentum while mitigating commercial and regulatory risks. First, prioritize investment in robust clinical evidence that measures patient-centered outcomes beyond acute procedural success, thereby aligning product claims with payer value frameworks and clinician expectations. Second, diversify sourcing strategies and consider nearshoring or dual-sourcing arrangements to reduce exposure to tariff shocks and logistics disruptions while improving responsiveness to regional demand shifts. Third, tailor go-to-market models by end-user setting, emphasizing simplified offerings and just-in-time logistics for ambulatory surgical centers, and advanced training and complication management support for cardiac centers and hospitals.
Furthermore, pursue modular commercial propositions that bundle device solutions with data services or outcome tracking, thereby strengthening value-based conversations with health systems. Engage proactively with regulators and reimbursement bodies to clarify evidentiary benchmarks and promote streamlined postmarket surveillance programs that generate actionable insights. Finally, maintain disciplined portfolio management that balances incremental product improvements with breakthrough innovation investments, ensuring that capital deploys where clinical impact and commercial viability align most strongly.
A transparent and rigorous research approach blending clinician interviews, technical device reviews, and regulatory analysis to validate clinical and commercial insights across the sector
This research synthesizes primary and secondary inputs to produce an objective assessment of the angioplasty balloon landscape. Primary research involved structured interviews with interventional cardiologists, vascular surgeons, procurement leaders, and device executives to capture experiential insights on device performance, clinical decision drivers, and procurement dynamics. These qualitative inputs were complemented by targeted device-level technical reviews and regulatory pathway analyses to align product features with approval and postmarket requirements. Secondary research encompassed peer-reviewed literature, clinical guidelines, and public regulatory documents to contextualize clinical efficacy and safety considerations and to validate themes emerging from stakeholder interviews.
Data triangulation ensured that findings reflect convergent evidence across clinician experience, regulatory precedent, and technical specifications. The methodology emphasized transparency in inclusion criteria for clinical studies and device comparators, and it prioritized evidence quality and applicability to contemporary practice. Finally, validation rounds with key opinion leaders and supply chain experts refined interpretations related to procurement behavior and tariff impacts, ensuring the analysis addresses both clinical realism and commercial pragmatism.
A synthesized conclusion tying clinical innovation, supply resilience, and regional strategy into a coherent pathway for sustainable adoption and improved patient outcomes
In summary, the angioplasty balloon sector sits at an inflection where clinical innovation, regulatory expectations, and commercial discipline converge. Drug-coated technologies and improvements in plain balloon design each contribute distinct value propositions across coronary and peripheral applications, while end-user diversity-from ambulatory surgical centers to specialty clinics-shapes adoption pathways and service expectations. Concurrent macro factors, including tariff-driven supply chain adjustments and regional regulatory variance, compel manufacturers to adopt flexible, regionally informed strategies that preserve clinical integrity while enabling commercial sustainability.
Looking ahead, durable success will favor organizations that couple compelling clinical evidence with resilient manufacturing and supply models, that engage payers with clear value narratives, and that support clinicians through training and outcome tracking. By integrating these strategic components, stakeholders can better navigate the evolving landscape and deliver device solutions that meet procedural demands, improve patient outcomes, and align with institutional priorities.
Note: PDF & Excel + Online Access - 1 Year
A concise orienting overview of clinical imperatives, care setting evolution, and device dynamics that shape procurement and innovation in angioplasty balloon technologies
This executive summary frames the contemporary angioplasty balloon landscape by situating device evolution within clinical needs, care pathway shifts, and enterprise-level priorities. Clinicians increasingly demand tools that balance acute procedural effectiveness with durable vessel patency and minimized repeat interventions, driving attention to both drug-coated balloon technologies and refinements in plain balloon mechanics. Concurrently, provider settings from high-acuity hospitals to ambulatory surgical centers reshape procedural volume distribution, influencing procurement cycles and capital allocation. The intersection of clinical efficacy, device safety profiles, and reimbursement realities determines adoption velocity across indications such as coronary and peripheral interventions, with the peripheral space further stratified by anatomical focus areas including carotid, iliac, lower limb, and renal.
In this context, industry stakeholders face a multifaceted decision environment. Device developers must align R&D priorities with evidence generation that resonates with interventional cardiologists and vascular surgeons while meeting regulatory expectations. Payers and providers increasingly evaluate devices through a value lens, prioritizing tools that demonstrably reduce downstream resource use. Therefore, the narrative underpinning angioplasty balloon development and commercialization centers on robust clinical outcomes, operational adaptability across ambulatory surgical centers and specialty clinics, and the capacity to navigate complex regulatory and procurement ecosystems without compromising patient outcomes.
An analysis of converging clinical, regulatory, and commercial forces reshaping angioplasty balloon adoption patterns and innovation priorities across care settings
The angioplasty balloon landscape has undergone substantive transformative shifts driven by converging clinical, regulatory, and commercial forces. Over recent years, the transition toward devices that address restenosis without permanent implant burdens has elevated drug-coated balloons from niche adjuncts to mainstream therapeutic considerations in peripheral interventions while prompting careful evaluation in coronary contexts. At the same time, improvements in balloon material science and delivery mechanisms have reduced procedural complications and enhanced lesion preparation, enabling safer treatment of complex anatomies such as calcified and tortuous vessels.
Moreover, stakeholder expectations now prioritize real-world evidence and patient-centric outcomes, prompting manufacturers to design trials and registries that capture durability, limb salvage, and quality-of-life metrics beyond short-term angiographic success. In parallel, health systems and payers emphasize cost-effective care pathways, thus incentivizing devices that reduce repeat procedures and hospital lengths of stay. As a result, companies face heightened pressure to demonstrate not only technical superiority or equivalence but also measurable improvements in downstream clinical and economic endpoints. These cumulative shifts compel coordinated strategies spanning clinical development, commercial positioning, and postmarket surveillance to secure durable adoption.
A detailed assessment of how 2025 cumulative tariff measures in the United States realigned supply chains, procurement practices, and manufacturing localization choices for cardiovascular device stakeholders
The introduction of cumulative United States tariff actions in 2025 created a material inflection point for supply chain decision-making and cost management in the cardiovascular device sector. Tariff-related cost pressures have prompted manufacturers and distributors to re-evaluate sourcing footprints, with many exploring greater regionalization of supply, renegotiation of supplier contracts, and stock optimization to mitigate landed cost volatility. In response, several device makers accelerated investments in domestic manufacturing capabilities or established dual-sourcing strategies to preserve continuity for high-demand product families while reducing exposure to tariff-driven margins compression.
Beyond direct cost implications, tariffs influenced strategic vendor consolidation and selection criteria, as providers and group purchasing organizations increasingly prioritized suppliers that could guarantee stable pricing and timely delivery. This shift also amplified the attractiveness of integrated supply models that bundle devices with procedural disposables and service agreements, enabling buyers to lock in predictable total cost of care. Importantly, the tariff environment reinforced the need for transparent cost components and scenario planning; procurement teams now require clearer decompositions of input cost drivers, logistics lead times, and contingency plans. Consequently, commercial negotiations and contracting structures have evolved to incorporate clauses addressing tariff pass-through, currency fluctuations, and collaborative supply risk management.
Granular segmentation intelligence revealing how product type, clinical indications across vascular territories, and diverse end-user settings intersect to shape adoption and procurement choices
Segment-specific dynamics reveal differentiated adoption pathways and commercial priorities across product, indication, and end-user classifications. Based on Product, the comparison between Drug Coated Balloon and Plain Balloon underscores diverging evidence requirements: drug-coated technologies rely on sustained clinical data to justify premium positioning given their therapeutic aim to mitigate restenosis, whereas plain balloons emphasize mechanical reliability, deliverability, and cost-efficiency for lesion preparation and short-duration interventions. Transitioning between these product categories requires careful economic and clinical rationale that resonates with both interventionalists and hospital procurement teams.
Based on Indication, contrasts between Coronary and Peripheral usage patterns shape device design and regulatory engagement strategies. Coronary applications often demand devices engineered for small-vessel precision and acute myocardial safety, while Peripheral interventions need long balloon lengths and robust profile management for tortuous anatomy; within the peripheral subset, clinical performance expectations vary across carotid, iliac, lower limb, and renal territories, each carrying unique anatomical and hemodynamic considerations that influence device selection. Based on End User, the procurement and utilization environment across Ambulatory Surgical Centers, Cardiac Centers, Hospitals, and Specialty Clinics affects product mix and service models: ambulatory centers prioritize compact logistics and rapid turnover, cardiac centers emphasize complex case capability and specialist training, hospitals balance capital investment with broad case mix, and specialty clinics focus on niche procedural excellence. These segmentation lenses intersect to create granular commercialization pathways, where clinical evidence, service support, and supply reliability determine the most viable adoption strategies for each segment.
A comprehensive view of regional regulatory diversity, clinical adoption drivers, and commercialization imperatives across the Americas, EMEA, and Asia-Pacific healthcare landscapes
Regional dynamics play a pivotal role in shaping regulatory strategies, commercial deployment, and clinical trial design across the Americas, Europe, Middle East & Africa, and Asia-Pacific. The Americas exhibit a concentration of advanced interventional programs and sophisticated payer mix considerations that accelerate evidence-driven adoption while exposing manufacturers to complex reimbursement pathways and procurement scrutiny. In contrast, regulatory pathways and healthcare reimbursement models across Europe, Middle East & Africa display heterogeneity, requiring nuanced market entry strategies that balance localized clinical partnerships and region-specific postmarket surveillance commitments.
Asia-Pacific presents both rapid procedural volume growth and diverse regulatory regimes, spurring manufacturers to tailor commercialization and manufacturing strategies for scale and affordability. Across these regions, companies must reconcile differing clinician preferences, institutional capabilities, and payer priorities; consequently, a single global commercialization model rarely suffices. Instead, regionalized product portfolios, localized clinical evidence generation, and adaptive pricing strategies become essential to navigate the variegated landscape, ensure compliance, and support sustainable adoption while enabling clinicians to access devices suited to their procedural and patient needs.
Strategic company-level perspectives highlighting how technology differentiation, clinical partnerships, and supply chain resilience drive competitive positioning and commercial success
Competitive dynamics among device manufacturers are increasingly characterized by dual vectors: technology differentiation and ecosystem services. Leading firms invest in coating chemistry improvements, balloon profile optimization, and delivery catheter ergonomics to secure clinical preference, while nimble innovators focus on niche advantages-such as specialized coatings or lesion preparation adjuncts-that target specific anatomical challenges. Strategic behaviors include alliance formation with clinical centers to generate real-world evidence, incremental product iterations to address clinician feedback, and selective acquisitions that fill technological gaps or expand geographic distribution.
Commercially, companies that combine strong clinical datasets with robust service offerings-training programs, procedural support, and outcome tracking-gain preferential access to tender processes and institutional formularies. Financially disciplined players emphasize supply chain resilience and lean manufacturing to protect margins in a pricing-constrained environment. Additionally, intellectual property around drug delivery mechanisms and coating stability remains a critical barrier to entry, prompting both defensive patent strategies and collaborative licensing arrangements. Overall, market leaders and challengers alike must balance R&D intensity with pragmatic commercialization frameworks that align evidence generation, regulatory submission timelines, and customer engagement models.
Actionable strategic imperatives for device makers and health system stakeholders to strengthen clinical evidence, stabilize supply chains, and optimize go-to-market models across care settings
Industry leaders should adopt a multifaceted approach to capitalize on clinical momentum while mitigating commercial and regulatory risks. First, prioritize investment in robust clinical evidence that measures patient-centered outcomes beyond acute procedural success, thereby aligning product claims with payer value frameworks and clinician expectations. Second, diversify sourcing strategies and consider nearshoring or dual-sourcing arrangements to reduce exposure to tariff shocks and logistics disruptions while improving responsiveness to regional demand shifts. Third, tailor go-to-market models by end-user setting, emphasizing simplified offerings and just-in-time logistics for ambulatory surgical centers, and advanced training and complication management support for cardiac centers and hospitals.
Furthermore, pursue modular commercial propositions that bundle device solutions with data services or outcome tracking, thereby strengthening value-based conversations with health systems. Engage proactively with regulators and reimbursement bodies to clarify evidentiary benchmarks and promote streamlined postmarket surveillance programs that generate actionable insights. Finally, maintain disciplined portfolio management that balances incremental product improvements with breakthrough innovation investments, ensuring that capital deploys where clinical impact and commercial viability align most strongly.
A transparent and rigorous research approach blending clinician interviews, technical device reviews, and regulatory analysis to validate clinical and commercial insights across the sector
This research synthesizes primary and secondary inputs to produce an objective assessment of the angioplasty balloon landscape. Primary research involved structured interviews with interventional cardiologists, vascular surgeons, procurement leaders, and device executives to capture experiential insights on device performance, clinical decision drivers, and procurement dynamics. These qualitative inputs were complemented by targeted device-level technical reviews and regulatory pathway analyses to align product features with approval and postmarket requirements. Secondary research encompassed peer-reviewed literature, clinical guidelines, and public regulatory documents to contextualize clinical efficacy and safety considerations and to validate themes emerging from stakeholder interviews.
Data triangulation ensured that findings reflect convergent evidence across clinician experience, regulatory precedent, and technical specifications. The methodology emphasized transparency in inclusion criteria for clinical studies and device comparators, and it prioritized evidence quality and applicability to contemporary practice. Finally, validation rounds with key opinion leaders and supply chain experts refined interpretations related to procurement behavior and tariff impacts, ensuring the analysis addresses both clinical realism and commercial pragmatism.
A synthesized conclusion tying clinical innovation, supply resilience, and regional strategy into a coherent pathway for sustainable adoption and improved patient outcomes
In summary, the angioplasty balloon sector sits at an inflection where clinical innovation, regulatory expectations, and commercial discipline converge. Drug-coated technologies and improvements in plain balloon design each contribute distinct value propositions across coronary and peripheral applications, while end-user diversity-from ambulatory surgical centers to specialty clinics-shapes adoption pathways and service expectations. Concurrent macro factors, including tariff-driven supply chain adjustments and regional regulatory variance, compel manufacturers to adopt flexible, regionally informed strategies that preserve clinical integrity while enabling commercial sustainability.
Looking ahead, durable success will favor organizations that couple compelling clinical evidence with resilient manufacturing and supply models, that engage payers with clear value narratives, and that support clinicians through training and outcome tracking. By integrating these strategic components, stakeholders can better navigate the evolving landscape and deliver device solutions that meet procedural demands, improve patient outcomes, and align with institutional priorities.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
194 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Increasing adoption of drug-coated balloons for peripheral arterial disease treatment improving clinical outcomes
- 5.2. Development of advanced balloon materials with enhanced biocompatibility and radial strength for complex lesions
- 5.3. Rising demand for low-profile delivery systems enabling complex lesion navigation in tortuous coronary arteries
- 5.4. Integration of intravascular imaging modalities with angioplasty balloons for accurate lesion measurement and therapy guidance
- 5.5. Regulatory approvals for next-generation drug-eluting balloons with controlled release profiles to minimize restenosis
- 5.6. Expansion of minimally invasive angioplasty procedures driving market growth in emerging Asia-Pacific and Latin America regions
- 5.7. Technological advancements in dual therapy balloons combining antiproliferative drug elution and vessel scaffolding functionalities
- 5.8. Strategic collaborations between medical device innovators and research institutions accelerating angioplasty balloon innovation
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Angioplasty Balloons Market, by Product Type
- 8.1. Coronary Angioplasty Balloons
- 8.1.1. Standard (Semi-Compliant) Balloons
- 8.1.2. Non-Compliant Balloons
- 8.1.3. Drug-Coated Balloons
- 8.1.4. Cutting and Scoring Balloons
- 8.2. Peripheral Angioplasty Balloons
- 8.2.1. Drug-Coated Peripheral Balloons
- 8.2.2. High-Pressure Peripheral Balloons
- 8.2.3. Specialty Peripheral Balloons
- 8.3. Neurovascular Balloons
- 8.3.1. Remodeling Balloons
- 8.3.2. Occlusion Balloons
- 9. Angioplasty Balloons Market, by Indication
- 9.1. Coronary
- 9.2. Peripheral
- 9.2.1. Carotid
- 9.2.2. Iliac
- 9.2.3. Lower Limb
- 9.2.4. Renal
- 10. Angioplasty Balloons Market, by Sales Channel
- 10.1. Direct Sales
- 10.2. Distributor and Dealer Sales
- 10.2.1. Large-Scale Distributor Networks
- 10.2.2. Independent Dealer Networks
- 10.3. Online and E-Procurement
- 11. Angioplasty Balloons Market, by End User
- 11.1. Ambulatory Surgical Centers
- 11.2. Cardiac Centers
- 11.3. Hospitals
- 11.4. Specialty Clinics
- 12. Angioplasty Balloons Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Angioplasty Balloons Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Angioplasty Balloons Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. Abbott Laboratories
- 15.3.2. Acrostak Int. Distr. Sarl
- 15.3.3. AngioDynamics, Inc.
- 15.3.4. B. Braun SE
- 15.3.5. Becton, Dickinson and Company
- 15.3.6. BIOTRONIK SE & Co. KG
- 15.3.7. Boston Scientific Corporation
- 15.3.8. Cardinal Health, Inc.
- 15.3.9. Cook Group Incorporated
- 15.3.10. Cordis
- 15.3.11. CSI
- 15.3.12. Hexacath
- 15.3.13. InSitu Technologies Inc.
- 15.3.14. Koninklijke Philips N.V
- 15.3.15. Lepu Medical Technology(Beijing)Co., Ltd.
- 15.3.16. Medtronic PLC
- 15.3.17. Merit Medical Systems, Inc.
- 15.3.18. MicroPort Scientific Corporation
- 15.3.19. Nipro Medical Corporation
- 15.3.20. PALEX MEDICAL, S.A.
- 15.3.21. phenox GmbH
- 15.3.22. Scitech Medical
- 15.3.23. Teleflex Incorporated.
- 15.3.24. Terumo Medical Corporation
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
